To describe the roles of the psychopharmacist in the use of neuroleptic therapy.
Setting:
A geriatric psychiatry ambulatory care clinic in a 400-bed Department of Veterans Affairs Medical Center, San Diego, California.
Conclusions:
In the pharmaceutical care model, the pharmacist is involved in several important roles in the provision of neuroleptic therapy. In the ambulatory care program, psychopharmacists provide important drug-related information to patients and consultation regarding potential neuroleptic-induced adverse effects. In addition, psychopharmacists serve as consultants to other clinicians concerning the risks associated with the use of neuroleptics and participate in neuroleptic-discontinuation clinics. Morbidity associated with neuroleptic-induced tardive dyskinesia has exposed healthcare providers to legal repercussions; therefore, pharmacy intervention may aid in the reduction of legal liability.
Get full access to this article
View all access options for this article.
References
1.
HeplerCDStrandLM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm1990; 47: 533–43.
2.
EvansLKirkRFWalkerPWRosenbluthSAMcDonaldJ. Medication maintenance of mentally ill patients by a pharmacist in a community setting. Am J Hosp Pharm1976; 33: 635–8.
3.
DugasJEBrownS. Community mental health centers: A milieu for expansion of pharmacist services. Hosp Pharm1978; 13: 78–87.
4.
EllenorGLDishmanBD. Pharmacist role in a mental health clinic as a primary provider. Paper presented at the 27th Annual American Society of Hospital Pharmacists Midyear Clinical Meeting, December 10, 1992, Orlando, FL.
5.
LacroJPKodsiABHarrisMJ. Multiple roles of a pharmacist in a teaching ambulatory care clinic. Paper presented at 28th Annual American Society of Hospital Pharmacist Midyear Clinical Meeting, December 7, 1993, Atlanta, GA.
6.
DishmanBREllenorGLLacroJPLohrJB. Pharmacists as primary care providers in a clozapine clinic. Paper presented at 28th Annual American Society of Hospital Pharmacists Midyear Clinical Meeting, December 7, 1993, Atlanta, GA.
7.
KarnoMNorquistGS. Schizophrenia: Epidemiology. In: KaplanHISadockBJ, eds. Comprehensive textbook of psychiatry/V. Baltimore, MD: Williams and Wilkins, 1989: 699–705.
8.
WraggRJesteDV. Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry1989; 146: 577–87.
9.
KaneJM. The current status of neuroleptic therapy. J Clin Psychiatry1989; 50: 322–8.
10.
PhillipsonMMaranvillJTJesteDVHarrisMJ. Antipsychotics. Clinic in geriatric medicine. 1990; 6: 411–22.
11.
BaldessariniRJColeJODavisJMGardosGPreskornSHSimpsonGM. Tardive dyskinesia: A task force report of the American Psychiatric Association. Washington, DC: American Psychiatric Association, 1980.
12.
KaneJMJesteDVBarnesTRECaseyDEColeJODavisJM. Tardive dyskinesia: A task force report of the American Psychiatric Association. Washington, DC: American Psychiatric Association, 1992.
WoernerMGKaneJMLiebermanJAAlvirJBergmannKJBorensteinM. The prevalence of tardive dyskinesia. J Clin Psychopharmacol1991; 11: 34–42.
17.
GlazerWMMorgenstemHSchoolerNBerkmanCSMooreDC. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry1990; 157: 585–92.
18.
AdlerLAPeselowERotrosenJDuncanELeeMRosenthalM. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry1993; 150: 1405–7.
19.
CatesMLuskKWellsBG. Are calcium-channel blockers effective in the treatment of tardive dyskinesia?Ann Phamacother1993; 27: 191–6.
20.
EganMTHydeTDAlbersGWElkashefAAlexanderRCReeveA. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry1992; 149: 773–7.
21.
ShriquiCLBradwejnJAnnableLJonesBD. Vitamin E in the treatment of tardive dyskinesia: A double-blind placebo controlled study. Am J Psychiatry1992; 149: 391–3.
22.
LoonenAJMVerweyHARoelsPRVan BavelLPDoorschotCH. Is diltiazem effective in treating the symptoms of (tardive) dyskinesia in chronic psychiatric patients? A negative, double-blind, placebo-controlled trial. J Clin Psychopharmacol1992; 12: 39–42.
23.
TrentCLMuhlWP. Professional liability insurance and the American psychiatrist. Am J Psychiatry1976; 132: 1312–4.
24.
WettsteinRM. Tardive dyskinesia and malpractice. Behav Sci Law1983; 1: 85–107.
25.
MillsMJEthS. Legal liability with psychotropic drug use: Extrapyramidal syndromes and tardive dyskinesia. J Clin Psychiatry1987; 48(suppl 9): 28–33.
26.
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Maine, Massachusetts, New Jersey, New York, North Dakota, Oregon, Puerto Rico, Texas, Utah, Washington, West Virginia, and Wisconsin. National Association of Boards of Pharmacy: Survey of Pharmacy Law. National Association of Boards of Pharmacy, 1991–92: 59.
27.
BrushwoodDB. The duty to counsel: Reviewing a decade of litigation. DICP Ann Pharmacother1991; 25: 195–204.
28.
SveskaKJ. Pharmacist liability. Am J Hosp Pharm1993; 50: 1429–36.
29.
MillsMJNorquistGSSheltonRCGelenbergAJVan PuttenT. Consent and liability with neuroleptics: The problem of tardive dyskinesia. Int J Law Psychiatry1986; 8: 243–52.
30.
GutheilTG. Medicolegal issues regarding tardive dyskinesia. In: JosephABYoungRR, eds. Movement disorders in neurology and neuropsychiatry. Cambridge, MA: Blackwell Scientific Publication, 1992: 46–50.
31.
LacroJPSewellDDWarrenKWoodySHarrisMJJesteDV. Improving documentation of consent for neuroleptic therapy. Hosp Community Psychiatry1993 (in press).
32.
RozovskyF. Consent to treatment: A practical guide. 2nd ed.Boston: Little, Brown, and Co., 1990.
33.
National institute of mental health: Abnormal involuntary movement scale (AIMS). Early Clinical Drug Evaluation Unit Intercom. 1979; 4: 3–6.
Informed consent in practice. In: AppelbaumPSLidzCWMeiselA, eds. Informed consent: Legal theory and clinical practice. New York: Oxford University Press, 1987: 151–74.
